Dow Surges 100 Points; Goldman Sachs Posts Upbeat Earnings
Portfolio Pulse from Lisa Levin
The Dow Jones rose by 100 points, while NASDAQ fell slightly. Goldman Sachs reported better-than-expected Q3 earnings, despite a decrease from the previous year. Energy shares climbed by 1%, while IT shares fell by 0.9%. SciSparc, Assembly Biosciences, and Olink Holding saw significant stock increases, while Evelo Biosciences, NetScout Systems, and Monte Rosa Therapeutics experienced decreases. Oil and gold prices rose slightly.
October 17, 2023 | 3:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shares of Assembly Biosciences shot up 93% after the company and Gilead announced a 12-year partnership to advance the research and development of novel antiviral therapies.
The significant increase in Assembly Biosciences' stock price is likely due to the company's recent partnership with Gilead, which could lead to the development of new antiviral therapies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Goldman Sachs reported better-than-expected Q3 earnings, beating the consensus of $5.31 per share with earnings of $5.47 per share.
Goldman Sachs' better-than-expected earnings report is likely to boost investor confidence and could lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Olink Holding's shares rose 66% after Thermo Fisher Scientific announced it will acquire the company.
The significant increase in Olink Holding's stock price is likely due to the company's recent acquisition announcement, which could provide the company with additional resources and support for growth and expansion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
SciSparc's shares shot up 119% after Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
The significant increase in SciSparc's stock price is likely due to the company's recent private placement, which could provide the company with additional capital for growth and expansion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Evelo Biosciences' shares dropped 52% after the company released top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.
The significant decrease in Evelo Biosciences' stock price is likely due to the company's recent clinical study results, which may have disappointed investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Monte Rosa Therapeutics' stock fell 20% as the company announced interim data from the Phase 1 dose escalation part of its ongoing phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors.
The decrease in Monte Rosa Therapeutics' stock price is likely due to the company's recent announcement of interim data from its ongoing study, which may have disappointed investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Shares of NetScout Systems were down 17% after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance.
The decrease in NetScout Systems' stock price is likely due to the company's weak Q2 results and lowered guidance, which could decrease investor confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100